Headshot of Ingrid Mayer, Global Clinical Head Breast Cancer and Breast Cancer Strategy, Research & Development, at AstraZeneca.

After 20 years as a medical oncologist in academia and clinical practice, my current role as the Global Clinical Strategy Head for Breast and Gynaecological Cancers allows me to pioneer and expand novel translational global research and innovative clinical trial development that accelerate the approval of established and novel drugs in the key areas of excellence at AstraZeneca, tumour resistance/targeted therapies, DNA damage response, antibody-drug conjugates and immuno-oncology.

My overarching vision is to promote paradigm-shifting and practice-changing treatments in breast and gynecological cancers to decrease mortality, morbidity and health disparities, as well as address the critical knowledge gaps in the breast and gynaecological cancer medical fields. 

Before joining AstraZeneca, I was a Professor of Medicine and Ingram Professor of Cancer Research at Vanderbilt University Medical Center for 18 years, with a successful track record of mentoring fellows and junior faculty throughout my career. As a trained breast cancer medical oncologist, I provided cutting-edge care to thousands of patients. I have extensive experience with novel therapeutics in phase I, II and III clinical trials, having been the principal investigator on more than 90 clinical trials spanning from phase I to phase III. My translational research in breast cancer focused on identifying targetable pathways and mechanisms of treatment resistance, which have been recognised and funded by the NCI (K23 and SPORE in Breast Cancer), SU2C/ AACR, Susan G. Komen Foundation and the Breast Cancer Research Foundation, and published in more than 135 peer-reviewed journals. I have chaired, co-chaired or been a member of many national and international health services cancer leadership committees in the US, such as ECOG-ACRIN Breast Core Committee, National Comprehensive Cancer Network (NCCN) Breast Cancer Panel of Experts, Translational Breast Cancer Research Consortium (TBCRC) amongst many others.

Bench-to-bed research has led us to alter the cancer treatment paradigm and practice, making treatments more effective and patient-centred. I am excited about the research we are pursuing that will help decrease mortality, morbidity and health disparities for cancer patients

Ingrid A. Mayer Global Clinical Strategy Head for Breast and Gynaecological Cancers, AstraZeneca

2018-2022

Komen Scholar

2013-2021

Top Doctors; Castle Connolly

2011-2021

VICC Star Award for Leadership in Cancer Clinical Investigation

Headshot of Ingrid Mayer, Global Clinical Head Breast Cancer and Breast Cancer Strategy, Research & Development, at AstraZeneca.

CURRENT ROLE

Global Clinical Strategy Head for Breast and Gynaecological Cancers, AstraZeneca

2022

Global Clinical Strategy Head for Breast Cancer, AstraZeneca

2021

Oncology Section Chief, Division of Hematology/ Oncology, Vanderbilt University Medical Center

2021

Membership Committee Member; European Society of Medical Oncology

 Featured publications

Veeva ID: Z4-61020
Date of preparation: January 2024